

## Thanatophoric Dysplasia, Types 1 and 2 (FGFR3), 13 Mutations

Thanatophoric dysplasia (TD) is a skeletal dysplasia that is often suspected based on clinical and/or radiographic findings of micromelia (marked shortening of the limbs) and dysmorphic features. There are two subtypes of TD; type 1 presents with bent femurs and rarely includes skull deformity (craniosynostosis) while type 2 is characterized by straight femurs and cloverleaf skull deformity.<sup>1</sup> Targeted testing for pathogenic variants can confirm a clinical diagnosis of TD in fetuses and neonates. TD is caused by pathogenic variants in the *FGFR3* gene, and the majority of pathogenic variants are de novo. The condition is almost always lethal, with death occurring due to respiratory insufficiency shortly after birth.

### Disease Overview

#### Symptoms

- Severe shortening of the extremities (bowed femurs in TD type 1)
- Redundant skin folds on limbs
- Short ribs/narrow thorax
- Hypotonia
- Brachydactyly with trident hand
- Macrocephaly
- Dysmorphic facial features (eg, frontal bossing, flat facies, low nasal bridge, proptotic eyes)
- Craniosynostosis (cloverleaf skull) in TD type 2

#### Prenatal Findings

Trimester	Ultrasound Findings
First	<ul style="list-style-type: none"> <li>• Increased nuchal translucency</li> <li>• Reverse flow in ductus venosus</li> <li>• Long bone shortening</li> </ul>
Second/third	<ul style="list-style-type: none"> <li>• Limb shortening &lt;5%; recognizable on ultrasound by ~18 wks gestation</li> <li>• Bent femurs in TD type 1</li> <li>• Cloverleaf skull in TD type 2</li> <li>• Narrow thorax</li> <li>• Polyhydramnios</li> <li>• Well-ossified skull and spine</li> </ul>

### Genetics

#### Gene

*FGFR3*

#### Tests to Consider

##### Thanatophoric Dysplasia, Types 1 and 2 (FGFR3) 13 Mutations 0051506

**Method:** Polymerase Chain Reaction/Fragment Analysis

Use to confirm clinical diagnosis of TD type 1 or type 2

##### Thanatophoric Dysplasia, Types 1 and 2 (FGFR3) 13 Mutations, Fetal 0051508

**Method:** Polymerase Chain Reaction/Fragment Analysis

Use to confirm diagnosis in a fetus with clinical suspicion of TD type 1 or type 2

See [Related Tests](#)

## Incidence

1/20,000<sup>1</sup>

## Inheritance

Autosomal dominant

Most cases are caused by de novo pathogenic variant in *FGFR3*; often associated with advanced paternal age.

## Penetrance

100%

## Test Interpretation

### Sensitivity/Specificity

#### Analytical Sensitivity/Specificity

99%

#### Clinical Sensitivity

99%

## Variants

Disease Type/Pathogenic Variant <sup>a</sup>	
TD Type 1	TD Type 2
c.742C>T (p.R248C)	c.1948A>G (p.K650E)
c.746C>G (p.S249C)	
c.1108G>T (p.G370C)	
c.1111A>T (p.S371C)	
c.1118A>G (p.Y373C)	
c.2419T>G (p.X807G)	
c.2419T>A (p.X807R)	
c.2420G>C (p.X807S)	
c.2420G>T (p.X807L)	
c.2421A>T (p.X807C)	
c.2421A>C (p.X807C)	
c.2421A>G (p.X807W)	

<sup>a</sup>13 pathogenic variants cause 99% of TD cases.

## Results

Result	Variant Detected	Interpretive Data
Positive	One pathogenic variant detected	Diagnosis of TD confirmed
Negative	No pathogenic variant detected	Not predicted to be affected with TD

## Limitations

- Diagnostic errors can occur due to rare sequence variations.
- Variants other than those targeted in FGFR3 are not detected.

## References

1. French T, Savarirayan R. [Thanatophoric dysplasia](#). In: Adam MP, Ardinger HH, Pagon RA, et al, eds. GeneReviews, University of Washington; 1993-2022. [Last update: June 2020; Accessed: Apr 2022]

## Related Information

[Skeletal Dysplasias](#)  
[Skeletal Dysplasia Panel](#)  
[Achondroplasia \(FGFR3\) 2 Mutations](#)

## Related Tests

[Skeletal Dysplasia Panel, Sequencing and Deletion/Duplication, Fetal 2012010](#)

**Method:** Massively Parallel Sequencing

[Skeletal Dysplasia Panel, Sequencing and Deletion/Duplication 2012015](#)

**Method:** Massively Parallel Sequencing/Exonic Oligonucleotide-based CGH Microarray

[Achondroplasia \(FGFR3\) 2 Mutations 0051266](#)

**Method:** Polymerase Chain Reaction/Fluorescence Resonance Energy Transfer (FRET)

[Achondroplasia \(FGFR3\) 2 Mutations, Fetal 0051265](#)

**Method:** Polymerase Chain Reaction/Fluorescence Monitoring

ARUP Laboratories is a nonprofit enterprise of the University of Utah and its Department of Pathology. 500 Chipeta Way, Salt Lake City, UT 84108  
(800) 522-2787 | (801) 583-2787 | aruplab.com | arupconsult.com  
Content Review April 2022 | Last Update May 2022